Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent
Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management o...
Saved in:
Published in | Clinical pharmacology in drug development Vol. 13; no. 1; pp. 111 - 116 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.01.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open‐label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study. |
---|---|
AbstractList | Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non-calcium-based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open-label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat C
and AUC
reductions were 53% and 45%, respectively. For Treatment C, C
and AUC
reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study. Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non-calcium-based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open-label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study.Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non-calcium-based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open-label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study. Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open‐label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study. Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open‐label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study. Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open‐label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat C max and AUC inf reductions were 53% and 45%, respectively. For Treatment C, C max and AUC inf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study. |
Author | Pai, Sudhakar M. Yamada, Hiroyuki |
Author_xml | – sequence: 1 givenname: Sudhakar M. surname: Pai fullname: Pai, Sudhakar M. email: pai@akrospharma.com organization: Akros Pharma Inc – sequence: 2 givenname: Hiroyuki surname: Yamada fullname: Yamada, Hiroyuki organization: Pharmaceutical Division, Japan Tobacco Inc |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37975611$$D View this record in MEDLINE/PubMed |
BookMark | eNp10U9LHDEUAPBQLPVPPfQLlEAvFbqaTHaTyVHXrRUEBVvoLWQyL25kJhmTjGWv_eTNuOqhYC554f3yeLy3j3Z88IDQJ0qOKSHViRna9pgyxt-hvYpyMhN8Xu-8xuz3LjpM6Z6UwwmldP4B7TIhxYJTuof-rqwFk3GwOK8B36xDGtY6Az5zvoWIb-EROt2XaKljE_yUCv7JnrmgH7XrdOM6lzdTiZXXMbRjyjp_w9rj66g7vIqbvI5hCA6SS_g2u37sdHb-Dp_egc8f0XuruwSHz_cB-vV99XP5Y3Z1fXG5PL2aGUYZn2lrqJGMLmrRCFvThrW6sSXTsIUVurKVZUDAtIYKIS1IXdVGzjlv6qq8K3aAvm7rDjE8jJCy6l0y0HXaQxiTqmpJy1QIl4V--Y_ehzH60p2qJCn1hOTzoj4_q7HpoVVDdL2OG_Uy3QKOtsDEkFIE-0ooUdPy1LQ8NS2v2JOt_eM62LwN1fLm_Pzpxz-lW5uH |
Cites_doi | 10.1002/cpdd.1252 10.1002/cpdd.923 10.1177/00912700122009872 10.1002/cpdd.1263 10.1002/cpdd.933 10.1016/j.semnephrol.2006.06.001 10.1345/aph.1M291 10.1093/ndt/gfv182.06 10.1111/1744-9987.13820 10.1093/ndt/gfi020 10.1053/j.ajkd.2003.08.027 10.1159/000517053 10.1111/1744-9987.13724 10.1093/ndt/gfh446 10.2165/00003495-200868010-00006 10.1093/ndt/gfm316 10.1159/000500487 10.1016/j.jchromb.2021.122754 10.1002/cpdd.752 10.1021/acsmedchemlett.7b00404 10.1159/000496929 10.1016/j.ekir.2021.04.037 |
ContentType | Journal Article |
Copyright | 2023, The American College of Clinical Pharmacology. American College of Clinical Pharmacology. |
Copyright_xml | – notice: 2023, The American College of Clinical Pharmacology. – notice: American College of Clinical Pharmacology. |
DBID | AAYXX CITATION NPM K9. 7X8 |
DOI | 10.1002/cpdd.1336 |
DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2160-7648 |
EndPage | 116 |
ExternalDocumentID | 37975611 10_1002_cpdd_1336 CPDD1336 |
Genre | article Journal Article |
GroupedDBID | -MK 05W 0R~ 1OC 33P 3SF 52U 52V 53G 8-1 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AAXRX AAYCA AAZKR ABCUV ABDBF ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BNHUX BOGZA BRXPI C45 DCZOG DPXWK DRFUL DRMAN DRSTM EBS EJD FUBAC G-S GODZA H13 HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LSO LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OVD P2W PQQKQ R.K ROL SUPJJ TEORI TUS WBKPD WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR WYJ ZZTAW AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY NPM K9. 7X8 |
ID | FETCH-LOGICAL-c3136-afc1c931587b7f81b3dabf136b35f7a2f2f3e0ecdc1779fe9a28c9466b8279f23 |
ISSN | 2160-763X 2160-7648 |
IngestDate | Fri Jul 11 15:38:02 EDT 2025 Tue Aug 12 12:51:03 EDT 2025 Mon Jul 21 05:54:07 EDT 2025 Tue Jul 01 00:19:15 EDT 2025 Wed Jan 22 16:15:47 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | ESRD HIF-PH sevelamer carbonate JTZ-951 enarodustat DDI pharmacokinetics clinical pharmacology CKD |
Language | English |
License | 2023, The American College of Clinical Pharmacology. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3136-afc1c931587b7f81b3dabf136b35f7a2f2f3e0ecdc1779fe9a28c9466b8279f23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 37975611 |
PQID | 2908277964 |
PQPubID | 2034576 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_2891756069 proquest_journals_2908277964 pubmed_primary_37975611 crossref_primary_10_1002_cpdd_1336 wiley_primary_10_1002_cpdd_1336_CPDD1336 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | January 2024 2024-01-00 2024-Jan 20240101 |
PublicationDateYYYYMMDD | 2024-01-01 |
PublicationDate_xml | – month: 01 year: 2024 text: January 2024 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Oxford |
PublicationTitle | Clinical pharmacology in drug development |
PublicationTitleAlternate | Clin Pharmacol Drug Dev |
PublicationYear | 2024 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2010; 44 2021; 1176 2021; 7 2017; 8 2021; 6 2021; 10 2023; 12 2004; 19 2015; 30 2006; 26 2020; 9 2019; 49 2005; 20 2022; 26 2008; 68 2007; 22 2003; 42 2001; 41 2019; 143 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_10_1 e_1_2_8_21_1 e_1_2_8_11_1 e_1_2_8_22_1 e_1_2_8_12_1 e_1_2_8_23_1 |
References_xml | – volume: 26 start-page: 261 issue: 4 year: 2006 end-page: 268 article-title: Pathogenesis of renal anemia publication-title: Semin Nephrol – volume: 8 start-page: 1320 year: 2017 end-page: 1325 article-title: Discovery of JTZ‐951: a HIF prolyl hydroxylase inhibitor for the treatment of renal anemia publication-title: ACS Med Chem Lett – volume: 26 start-page: 345 issue: 2 year: 2022 end-page: 356 article-title: Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies publication-title: Ther Apher Dial – volume: 10 start-page: 884 issue: 8 year: 2021 end-page: 898 article-title: Thorough QT/QTc evaluation of the cardiac safety of enarodustat (JTZ‐951), an oral erythropoiesis‐stimulating agent, in healthy adults publication-title: Clin Pharmacol Drug Dev – volume: 6 start-page: 1840 issue: 7 year: 2021 end-page: 1849 article-title: A Phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study publication-title: Kidney Int Rep – volume: 20 start-page: 2288 issue: 10 year: 2005 end-page: 2289 article-title: Drug interaction between sevelamer and furosemide publication-title: Nephrol Dial Transplant – volume: 12 start-page: 683 issue: 7 year: 2023 end-page: 690 article-title: Pharmacokinetics of enarodustat in non‐Japanese and Japanese healthy subjects and in patients with end‐stage renal disease on hemodialysis publication-title: Clin Pharmacol Drug Dev – volume: 41 start-page: 193 issue: 2 year: 2001 end-page: 198 article-title: Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate‐binding polymer, does not interfere with digoxin or warfarin pharmacokinetics publication-title: J Clin Pharmacol – volume: 1176 year: 2021 article-title: A highly sensitive and selective UPLC‐MS/MS assay for the determination of enarodustat (JTZ‐951) in human plasma publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 49 start-page: 165 issue: 2 year: 2019 end-page: 174 article-title: A placebo‐controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long‐term trial publication-title: Am J Nephrol – volume: 68 start-page: 85 issue: 1 year: 2008 end-page: 104 article-title: Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end‐stage renal disease on haemodialysis publication-title: Drugs – volume: 26 start-page: 679 issue: 4 year: 2022 end-page: 693 article-title: Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: a review of the evidence publication-title: Ther Apher Dial – volume: 42 start-page: 1253 issue: 6 year: 2003 end-page: 1259 article-title: Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin publication-title: Am J Kidney Dis. – volume: 10 start-page: 463 issue: 5 year: 2021 end-page: 470 article-title: Hemodialysis clearance of enarodustat (JTZ‐951), an oral erythropoiesis stimulating agent, in patients with end‐stage renal disease publication-title: Clin Pharmacol Drug Dev – volume: 19 start-page: 2630 issue: 10 year: 2004 end-page: 2633 article-title: The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation publication-title: Nephrol Dial Transplant – volume: 9 start-page: 728 issue: 6 year: 2020 end-page: 741 article-title: A mass balance study of C‐labeled JTZ‐951 (enarodustat), a novel orally available erythropoiesis‐stimulating agent, in patients with end‐stage renal disease on hemodialysis publication-title: Clin Pharmacol Drug Dev – volume: 12 start-page: 667 issue: 7 year: 2023 end-page: 682 article-title: Evaluation of drug–drug interaction potential of enarodustat (JTZ‐951) using a cytochrome P450 probe cocktail publication-title: Clin Pharmacol Drug Dev – volume: 22 start-page: 2900 year: 2007 end-page: 2908 article-title: Serum erythropoietin concentrations and responses to anemia in patients with or without kidney disease publication-title: Nephrol Dial Transplant – volume: 44 start-page: 127 issue: 1 year: 2010 end-page: 134 article-title: Sevelamer carbonate publication-title: Ann Pharmacother – volume: 30 start-page: iii293 issue: 3 year: 2015 end-page: iii294 article-title: JTZ‐951, a novel HIF‐PHD inhibitor, demonstrates increases in hemoglobin, iron mobilization, reproducible pharmacokinetics, and safety following once daily administration for 15 days in patients with anemia receiving hemodialysis publication-title: Nephrol Dial Transplant – volume: 143 start-page: 77 issue: 2 year: 2019 end-page: 85 article-title: Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo‐controlled Phase 2b trial followed by long‐term trial publication-title: Nephron – volume: 7 start-page: 494 issue: 6 year: 2021 end-page: 502 article-title: A Phase 3 study of enarodustat (JTZ‐951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study publication-title: Kidney Dis (Basel) – ident: e_1_2_8_15_1 doi: 10.1002/cpdd.1252 – ident: e_1_2_8_12_1 doi: 10.1002/cpdd.923 – ident: e_1_2_8_21_1 doi: 10.1177/00912700122009872 – ident: e_1_2_8_14_1 doi: 10.1002/cpdd.1263 – ident: e_1_2_8_11_1 doi: 10.1002/cpdd.933 – ident: e_1_2_8_3_1 doi: 10.1016/j.semnephrol.2006.06.001 – ident: e_1_2_8_16_1 doi: 10.1345/aph.1M291 – ident: e_1_2_8_22_1 doi: 10.1093/ndt/gfv182.06 – ident: e_1_2_8_5_1 doi: 10.1111/1744-9987.13820 – ident: e_1_2_8_20_1 doi: 10.1093/ndt/gfi020 – ident: e_1_2_8_18_1 doi: 10.1053/j.ajkd.2003.08.027 – ident: e_1_2_8_9_1 doi: 10.1159/000517053 – ident: e_1_2_8_10_1 doi: 10.1111/1744-9987.13724 – ident: e_1_2_8_19_1 doi: 10.1093/ndt/gfh446 – ident: e_1_2_8_17_1 doi: 10.2165/00003495-200868010-00006 – ident: e_1_2_8_2_1 doi: 10.1093/ndt/gfm316 – ident: e_1_2_8_8_1 doi: 10.1159/000500487 – ident: e_1_2_8_23_1 doi: 10.1016/j.jchromb.2021.122754 – ident: e_1_2_8_13_1 doi: 10.1002/cpdd.752 – ident: e_1_2_8_4_1 doi: 10.1021/acsmedchemlett.7b00404 – ident: e_1_2_8_6_1 doi: 10.1159/000496929 – ident: e_1_2_8_7_1 doi: 10.1016/j.ekir.2021.04.037 |
SSID | ssj0000601114 |
Score | 2.266519 |
Snippet | Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in... Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 111 |
SubjectTerms | Bioavailability CKD clinical pharmacology DDI enarodustat ESRD HIF‐PH JTZ‐951 pharmacokinetics sevelamer carbonate |
Title | Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpdd.1336 https://www.ncbi.nlm.nih.gov/pubmed/37975611 https://www.proquest.com/docview/2908277964 https://www.proquest.com/docview/2891756069 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVbCqMvY9_L1g1tjDJo3NpSHNmPzUcJg22BpdA3I0tyE7rYwYkL2eN--a4k23GWFba9GMVSJPA5vr5X0j1C6EPIvNh3XekIzqQDX2jlcOH6jhB-V4S-jGmgs5E_f-mNL7ufrvyr7YS-yS5Zx6fixx_zSv4HVbgHuOos2X9Atu4UbkAZ8IUrIAzXv8K4lB4ul_kns2y1nIHveNLXGog52IFbBYBDacDzWE-Tq3JtQB9ByW_5_LtV6Tar7KOUa_VXnWFkt3SefNXJ-6N8Y49SgJB6vgLndL4wJ37p2ZTratdMJXVQpVkut4LYJq9Q5sV1lZ_V3GozsYdhfyvkjN9oRaHaCPEFl8avHc_zbFPczJvTE6TbmJ5QxowRr-c6rGf1NGubS_e4ZQ1oaXr3DLsVihVLKU8hqu412wAmy4VBmLKQgT_obb9t9Y7Dquo-OiAQUJAWOjjvD_sX9Xyc1qWB2LASn3LJWT3YIXpQ_X3Xe9kLSXYjHOOiTB-hh2Vsgc8tUR6jeyp9go4nFotNB0-3uXarDj7GkwZKT9FPyyacJRgYgms2YcsmXLMJ12zCWWra_sYm3UWDTR3MU6y5hHe5hBtcwoZLz9DlxWg6GDvlCR2OoB7tOTwRngip5wcsZglEQFTyOIGamPoJ4yQhCVWuElJ4jIWJCjkJhD7RIA4I_Cb0OWqlWapeItxNpOIeh29vV0A5DiQEusQVkio_hKCjjd5XTz5aWiGWyEpuk0gjFWmk2uiowiQq39NVREJwc5lOuW6jd3U1WFG9NMZTlRXQJgjBj4ZgPmyjFxbLepQK-zb6aMC9e_hoMBkOdeHVnZ28Rofbt-QItdZ5od6AW7uO35aM_AV0lqio |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+the+Phosphate+Binder+Sevelamer+Carbonate+on+the+Bioavailability+of+Enarodustat%2C+an+Oral+Erythropoiesis+Stimulating+Agent&rft.jtitle=Clinical+pharmacology+in+drug+development&rft.au=Pai%2C+Sudhakar+M&rft.au=Yamada%2C+Hiroyuki&rft.date=2024-01-01&rft.eissn=2160-7648&rft.volume=13&rft.issue=1&rft.spage=111&rft_id=info:doi/10.1002%2Fcpdd.1336&rft_id=info%3Apmid%2F37975611&rft.externalDocID=37975611 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2160-763X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2160-763X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2160-763X&client=summon |